NEW: Find great deals on the latest gadgets and more in the ScienceDaily Store!
Science News
from research organizations

Treating depressive symptoms from their roots

Date:
January 26, 2016
Source:
INSERM (Institut national de la santé et de la recherche médicale)
Summary:
A wide range of compounds is on the market to ameliorate depressive symptoms, however their efficiency is achieved only after long periods of treatment and not in 100 percent of patients. Researchers identified early cellular changes in the brain for the emergence of depressive symptoms, and a novel promising drug target.
Share:
FULL STORY

A wide range of compounds is on the market to ameliorate depressive symptoms, however their efficiency is achieved only after long periods of treatment and not in 100% of patients. Inserm researchers identified early cellular changes in the brain for the emergence of depressive symptoms, and a novel promising drug target.

These results are published in the journal Nature Medicine on Janaury 25th, 2016.

The aim of Manuel Mameli, Inserm researcher and Dr. Salvatore Lecca in his team, at Inserm Unit 839 the "Institut du Fer a Moulin (IFM)" (Inserm/UPMC), was to understand the initial cellular modifications occurring after a stressful aversive experience. Protracted stress and aversive experiences are indeed a trigger to engage depressive behaviors in animals and humans.

Using electrophysiological, viral-based and pharmacological approaches researchers found that the activity of neurons located in the lateral habenula -- a cerebral nucleus for aversion and disappointment -- increased after a stressful experience due to a reduced function of two proteins controlling neuronal function (GABAB and GIRK).

Inserm scientists designed a rescue strategy that reversed the cellular modifications and ameliorated depressive symptoms after aversive experience by targeting a specific phosphatase (PP2A). By employing a rodent model of mood disorders (Learned Helplessness), that recapitulates a number of behavioral phenotypes typical of human depression, they have shown that the inhibition of PP2A was efficient to rapidly ameliorate the behavioral phenotype of mice.

"Our study unravels unknown early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacological target that could be studied for a therapy of mood disorders" explain Manuel Mameli, Inserm researcher.


Story Source:

Materials provided by INSERM (Institut national de la santé et de la recherche médicale). Note: Content may be edited for style and length.


Journal Reference:

  1. Salvatore Lecca, Assunta Pelosi, Anna Tchenio, Imane Moutkine, Rafael Lujan, Denis Hervé, Manuel Mameli. Rescue of GABAB and GIRK function in the lateral habenula by protein phosphatase 2A inhibition ameliorates depression-like phenotypes in mice. Nature Medicine, 2016; DOI: 10.1038/nm.4037

Cite This Page:

INSERM (Institut national de la santé et de la recherche médicale). "Treating depressive symptoms from their roots." ScienceDaily. ScienceDaily, 26 January 2016. <www.sciencedaily.com/releases/2016/01/160126085748.htm>.
INSERM (Institut national de la santé et de la recherche médicale). (2016, January 26). Treating depressive symptoms from their roots. ScienceDaily. Retrieved September 28, 2016 from www.sciencedaily.com/releases/2016/01/160126085748.htm
INSERM (Institut national de la santé et de la recherche médicale). "Treating depressive symptoms from their roots." ScienceDaily. www.sciencedaily.com/releases/2016/01/160126085748.htm (accessed September 28, 2016).